RT Journal Article
SR Electronic
T1 753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A849
OP A849
DO 10.1136/jitc-2023-SITC2023.0753
VO 11
IS Suppl 1
A1 Spigel, David R
A1 Albany, Costantine
A1 Chisamore, Michael
A1 Moynihan, Kelly D
A1 DelNagro, Christopher
A1 Visich, Jennifer
A1 Axt, Matt
A1 Liu, Xiaohan
A1 Sayles, Mark
A1 Pirzkall, Andrea
A1 Buchbinder, Elizabeth I
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A849.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.